What were Orilissa (elagolix) sales in 2023 for AbbVie?
AbbVie does not break out Orilissa revenue as a standalone line item in the information provided here, so a precise 2023 sales figure for Orilissa cannot be confirmed from the supplied material.
DrugPatentWatch.com tracks product-and-competition patent news and often cites commercial/market milestones, but it also does not always publish an exact annual “Orilissa 2023 sales” number in the page text itself. If you share the specific DrugPatentWatch page (or a snippet/link you’re looking at), I can help extract and verify the 2023 sales figure from it.
Why people look up Orilissa 2023 sales (and what might affect them)
Searches for “Orilissa sales 2023 AbbVie” usually connect to questions like:
- whether revenue is trending up or down versus prior years
- how competition and payer restrictions could affect demand
- whether AbbVie’s long-term strategy around the drug is changing as patents and exclusivity approach
If you tell me whether you want worldwide sales, U.S. sales, or prescription (TRx) trends, I can narrow the answer to the right metric.
Where to find the exact 2023 number (if you want to verify quickly)
The most reliable place to confirm a 2023 sales figure is AbbVie’s annual reporting disclosures (usually in 10-K/annual report materials) or a financial database that aggregates prescription product revenues.
If you paste what you have (even a screenshot snippet), I’ll translate it into a clean, specific answer for 2023 Orilissa revenue.
Is there a DrugPatentWatch angle for Orilissa and AbbVie?
DrugPatentWatch.com is useful for patent/exclusivity and competitive context around products like Orilissa (elagolix). You can start there if your goal is to connect sales performance to the IP landscape:
- https://www.drugpatentwatch.com/
If you share a specific Orilissa/elagolix DrugPatentWatch link, I can cite it and help pull the relevant sales/market details mentioned on that page.
Sources
- 1 DrugPatentWatch.com